Toxicities and Long Term Survival After Autologous Hematopoietic Stem Cell Transplantation for Older Patients with Relapsed/Refractory Hodgkin Lymphoma

Gunjan L. Shah(Cornell University), Matthew J. Matasar(Rutgers, The State University of New Jersey), Joachim Yahalom(Unknown), Paul A. Hamlin, Hillary Glick(Memorial Sloan Kettering Cancer Center), Craig S. Sauter(Memorial Sloan Kettering Cancer Center), Sean M. Devlin(Memorial Sloan Kettering Cancer Center), Parastoo B. Dahi(Memorial Sloan Kettering Cancer Center), Alison J. Moskowitz, Sergio Giralt(Memorial Sloan Kettering Cancer Center), Connie Lee(University of Michigan), Craig H. Moskowitz(University of Miami), Satyajit Kosuri(University of Chicago), David J. Straus(Memorial Sloan Kettering Cancer Center)
Hematological Diseases and Therapies
January 1, 2019
Cited by 0

Related Papers

Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
|Science Translational Medicine|2014|2.5k
CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION
|British Journal of Haematology|1998|1.5k
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.
|Journal of Clinical Oncology|1997|1.3k
Engraftment of Allogeneic Hematopoietic Progenitor Cells With Purine Analog-Containing Chemotherapy: Harnessing Graft-Versus-Leukemia Without Myeloablative Therapy
|Blood|1997|1.2k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.1k